参松养心胶囊治疗慢性心力衰竭合并室性早搏患者的疗效观察

发布时间：2018-01-08 17:12

本文关键词：参松养心胶囊治疗慢性心力衰竭合并室性早搏患者的疗效观察　出处：《中国药物经济学》2017年04期 　论文类型：期刊论文

【摘要】：目的探讨参松养心胶囊治疗慢性心力衰竭合并室性早搏患者的疗效。方法以广东省怀集县人民医院2015年1月至2016年10月收治的88例慢性心力衰竭合并室性早搏患者为观察组(给予参松养心胶囊治疗),以同期收治的60例慢性心力衰竭合并室性早搏患者为对照组(给予普罗帕酮治疗),观察两组患者的临床疗效。结果治疗后,观察组患者心电图改善总有效率明显高于对照组,差异有统计学意义(P0.05);治疗后,观察组患者症状好转率明显高于对照组,差异有统计学意义(P0.05);观察组患者不良反应发生率明显低于对照组,差异有统计学意义(P0.05)。结论采用参松养心胶囊对慢性心力衰竭合并室性早搏患者进行治疗,不仅心电图以及症状改善情况良好,具有显著治疗效果,而且不良反应发生率较低,药物安全性高,对患者损伤小。
[Abstract]:Objective to investigate the therapeutic effect of Shensong Yangxin capsule on chronic heart failure complicated with ventricular premature beat. Methods 88 cases of chronic heart failure were treated from January 2015 to October 2016 in Huaiji County people's Hospital of Guangdong Province. Patients with exhausted ventricular premature beats were treated as observation group (. Give Shensong Yangxin capsule treatment). 60 patients with chronic heart failure complicated with ventricular premature beats were treated as control group (treated with propafenone). The total effective rate of ECG improvement in the observation group was significantly higher than that in the control group, and the difference was statistically significant (P 0.05). After treatment, the improvement rate of symptoms in the observation group was significantly higher than that in the control group, and the difference was statistically significant (P 0.05). The incidence of adverse reactions in the observation group was significantly lower than that in the control group (P 0.05). Conclusion Shensong Yangxin capsule is used to treat chronic heart failure patients with ventricular premature beat. Not only the electrocardiogram and symptoms were improved well, but also the incidence of adverse reactions was low, the drug safety was high, and the injury to the patients was small.
【作者单位】：广东省怀集县人民医院心内科;
【分类号】：R259
【正文快照】： 慢性心力衰竭属于临床常见疾病,病情危急。室性早搏属于一种室性心律失常现象,其经常发作可逐渐发展为心室颤动以及室性心动过速,最终出现黑蒙以及晕厥甚至是猝死的不良结局。慢性心力衰竭往往伴随室性早搏,致使病情更为复杂,治疗极为不易。普罗帕酮具有抗心律失常的功效,可应

【相似文献】